FDA Approves Wegovy Pill, Igniting New Front in Billion-Dollar Weight-Loss Drug Race
The FDA has approved a once-daily pill version of Novo Nordisk's blockbuster weight-loss drug Wegovy, offering a new option versus the weekly shot and escalating competition with Eli Lilly.
The U.S. Food and Drug Administration (FDA) today approved a daily pill version of Novo Nordisk's blockbuster anti-obesity drug, . The move provides an alternative to the original weekly injection and is set to intensify the rivalry with Eli Lilly as pharmaceutical giants race to dominate the soaring weight-loss market with more convenient options.
Pill vs. Shot: Convenience Without Compromise?
Both the new pill and the original injection contain the same active ingredient, , a drug that mimics a natural hormone to signal fullness to the brain and gut. "This allows patients with obesity who want to lose weight to have a choice between a once weekly injection or a daily tablet," said Martin Holst Lange, chief scientific officer at Novo Nordisk.
According to clinical trial results published in the New England Journal of Medicine, participants taking the pill achieved an average weight loss of by . Nearly of people lost or more of their body weight. However, the trial also highlighted a potential weakness of pills: adherence. Investigators estimated that with perfect daily adherence, weight loss could reach —nearly identical to results from the injectable version.
The Oral Arms Race Heats Up
The new pill is essentially a higher-dose version of Rybelsus, another Novo Nordisk oral drug approved in 2019 for type 2 diabetes. The pill contains of semaglutide, compared to in Rybelsus, as higher doses are needed for obesity treatment. Novo says the starting dose will be available in early January for with savings offers.
Meanwhile, competitor Eli Lilly isn't standing still. The company is developing its own daily pill, called . While trial results showed a slightly lower average weight loss of , has a key advantage: it comes with no food or water restrictions. Eli Lilly plans to submit its pill for FDA approval by the end of this year, setting the stage for a head-to-head battle in the oral obesity drug market.
This approval is more than a new product; it's a platform expansion. By turning a blockbuster injectable into an oral drug, Novo Nordisk is lowering the barrier to entry for millions of needle-averse patients. The next battlefront won't just be about peak efficacy, but about a portfolio of options—pills, injections, and maybe future formulations—that lock users into a single company's ecosystem.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
The US FDA has approved the first-ever pill form of Novo Nordisk's blockbuster weight-loss drug, Wegovy. Showing comparable results to the injection in trials, the daily pill is set to launch in January 2026.
The U.S. Federal Communications Commission (FCC) has banned new foreign-made drones, including those from DJI, adding them to its 'Covered List' due to national security risks.
AI MagicX is offering a lifetime deal for $59.97 on its AI suite, which includes writing, design, coding, and chatbot tools, normally priced at $972.
A 60 Minutes segment censored by CBS News has leaked online after a Canadian TV partner aired it. The incident showcases the difficulty of controlling information in the digital age.